iBio, Inc.

Last price update: 07 Oct 24 23:00 GMT

Price:
$2.66
Open:
$2.50
Previous close:
$2.19
Day's range:
$2.26 - $2.78
Year's range:
$1.02 - $7.80
Net Income per Share:
-4.03
Price-to-Earnings ratio:
-0.66
52-week Price Range:
$1.95
Volume:
$1,380,247.00
Average volume:
$72,206.00

Company profile for iBio, Inc.

iBio, Inc. logo

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Stock exchanges:
AMEX
Sector:
Healthcare
Industries:
Biotechnology
Ticker:
IBIO
CIK:
0001420720
ISIN:
US4510332038
Website:
https://www.ibioinc.com
Phone:
979 446 0027
Origin:
United States
Employees:
105